Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma

Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma

Abstract Unesbulin is being investigated in combination with dacarbazine (DTIC) as a potential therapeutic agent in patients with advanced leiomyosarcoma (LMS). This paper reports the pharmacokinetics (PK) of unesbulin, DTIC, and its unreactive surrogate metabolite 5‐aminoimidazole‐4‐carboxamide (AI...

Full description

Bibliographic Details
Main Authors: Lan Gao, Diksha Kaushik, Brian A. Van Tine, Matthew A. Ingham, Steven Attia, Christian F. Meyer, Gary K. Schwartz, Pius Maliakal, John D. Baird, Jiyuan Ma, Rosemary Barrett, Dhiren D'Silva, Kylie O'Keefe, Ronald Kong
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13709

Internet

https://doi.org/10.1111/cts.13709

Similar Items